Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
118859925 | 11885992 | 5 | F | 201508 | 20160705 | 20160104 | 20160712 | EXP | US-BIOGEN-2015BI122401 | BIOGEN | 40.39 | YR | F | Y | 0.00000 | 20160712 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
118859925 | 11885992 | 1 | PS | TYSABRI | NATALIZUMAB | 1 | Intravenous (not otherwise specified) | INFUSED OVER 1 HOUR | N | 125104 | 300 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION | ||||||
118859925 | 11885992 | 2 | SS | TYSABRI | NATALIZUMAB | 1 | Intravenous (not otherwise specified) | N | 125104 | 300 | MG | CONCENTRATE FOR SOLUTION FOR INFUSION |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
118859925 | 11885992 | 1 | Multiple sclerosis |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
118859925 | 11885992 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
118859925 | 11885992 | Cervix carcinoma | |
118859925 | 11885992 | Drug effect decreased | |
118859925 | 11885992 | Gait disturbance | |
118859925 | 11885992 | Human papilloma virus test positive |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
118859925 | 11885992 | 2 | 20091008 | 20160412 | 0 |